D1.492 - Efficacy and safety of a combined nasal spray with a fixed dose of mometasone and olopatadine for the treatment of allergic rhinitis in pets under save ongoing exposure to epidermal allergens

Pet allergy is a common cause of respiratory allergic diseases. There is a limited number of studies assessing the standard antiallergic therapy efficacy in patients with epidermal sensitization.

30 adult patients with confirmed AR caused by sensitization to epidermal allergens were include in the study. A prerequisite was continued contact with an allergenic pet for at least 8 hours a day throughout the study. During 90 days all patients received the mometasone+olopatadine nasal spray (100/2400 mcg twice a day), in accordance to instruction. The efficacy and safety were evaluated by the symptoms dynamic, TNSS, RQLQ, VAS questionnaires, and the adverse events (AEs) registration. 

The use of the fixed combination of mometasone and olopatadine allowed to control over the AR symptoms, including congestion, runny nose, sneezing, and itching, and improved the quality of life for all patients, despite ongoing contact with causative allergens. According to the questionnaires, the TNSS score significantly decreased after 30 days of treatment compared to baseline (0.56 [0;1] vs 2.5 [2; 3]). The total score on the VAS before treatment was 70.76 [60; 100], which decreased to 20.5 [10; 40] after 1 month of therapy, and further to 10.8 [0; 40] after 90 days. No serious adverse events (AEs) were reported among the participants. Among AEs, the most frequently reported were nasal bleeding in 15 (50%) patients and a sensation of discomfort in the nose in 7 (21%) patients. These AEs were deemed non-serious and did not require additional therapy.

Mometasone+olopatadine nasal spray has demonstrated high efficacy and safety in patients with hypersensitivity to epidermal allergens under conditions of continuing exposure to a causal allergen.